
|Videos|October 22, 2013
Treatment Decisions for Patients With Melanoma
Author(s)Omid Hamid, MD
Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses treatment decisions for patients with melanoma.
Advertisement
Clinical Pearls
Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses treatment decisions for patients with melanoma.
- When necessary, physicians should refer a patient for a second opinion
- Physicians must research the benefits of immunotherapy and the kinetics of response
- Physicians should not follow a treatment recommendation without considering their own clinical experience and the desires of the patient
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































